Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the imm ....Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the immune system when a vaccine enters the skin, as might happen by injection. Experimenting with laboratory mice and a special vaccine-injecting Nanopatch that is attached to each mouse's ear, we are starting to understand how a vaccine affects the immune cells in the skin. In the future we plan to apply this knowledge to improve vaccination in people.Read moreRead less
Targeting the delivery of cytotoxic agents to tumour cells using novel minicells as drug delivery vehicles and engineered, bispecific antibodies. Cancer persists as a major cause of morbidity and mortality globally. A major problem is the non-specific action of drugs used for treatment. The minicell is a drug delivery vehicle, capable of packaging a variety of drugs. The project will develop tumour-specific antibodies that will target minicells to tumours, improving cancer survival rates.